

Cochrane re-arranged: Support for policies to vaccinate

Vaccine

31, 6030-6033

DOI: [10.1016/j.vaccine.2013.09.063](https://doi.org/10.1016/j.vaccine.2013.09.063)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Influenza Vaccines: Unmet Needs and Recent Developments. <i>Infection and Chemotherapy</i> , 2013, 45, 375.	1.0	20
2	2012-2013 Seasonal Influenza Vaccine Effectiveness against Influenza Hospitalizations: Results from the Global Influenza Hospital Surveillance Network. <i>PLoS ONE</i> , 2014, 9, e100497.	1.1	27
3	Effectiveness of post-exposition prophylaxis with oseltamivir in nursing homes: a randomised controlled trial over four seasons. <i>Emerging Themes in Epidemiology</i> , 2014, 11, 13.	1.2	18
5	Advances in Universal Influenza Virus Vaccine Design and Antibody Mediated Therapies Based on Conserved Regions of the Hemagglutinin. <i>Current Topics in Microbiology and Immunology</i> , 2014, 386, 301-321.	0.7	115
6	Immunosenescence: influenza vaccination and the elderly. <i>Current Opinion in Immunology</i> , 2014, 29, 38-42.	2.4	228
7	Intranasally administered Endocineâ,¢ formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets. <i>Vaccine</i> , 2014, 32, 3307-3315.	1.7	15
8	Practical prevention of nosocomial influenza transmission, â€”a hierarchical controlâ€™ issue. <i>Occupational Medicine</i> , 2015, 65, kqv155.	0.8	5
9	Estimating the Effect of Influenza Vaccination on Nursing Home Residentsâ€™ Morbidity and Mortality. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1798-1804.	1.3	26
10	Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013. <i>Antiviral Therapy</i> , 2015, 20, 753-761.	0.6	5
11	Winning a Race Against Evolving Pathogens with Novel Platforms and Universal Vaccines. , 2015, , 251-287.		2
12	Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015. <i>PLoS ONE</i> , 2015, 10, e0132195.	1.1	31
13	An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model. <i>PLoS ONE</i> , 2015, 10, e0133606.	1.1	32
14	Novel observational study designs with new influenza vaccines. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 253-254.	4.6	0
15	A literature review to identify factors that determine policies for influenza vaccination. <i>Health Policy</i> , 2015, 119, 697-708.	1.4	12
16	Influenza vaccination: a summary of Cochrane Reviews. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 205-213.	1.3	3
17	Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors. <i>Vaccine</i> , 2015, 33, 734-741.	1.7	46
18	Advances in the development of influenza virus vaccines. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 167-182.	21.5	496
19	Fluarix quadrivalent vaccine for influenza. <i>Expert Review of Vaccines</i> , 2015, 14, 1055-1063.	2.0	14

#	ARTICLE	IF	CITATIONS
20	Randomized, Controlled Trial of High-Dose Influenza Vaccine Among Frail Residents of Long-Term Care Facilities. <i>Journal of Infectious Diseases</i> , 2015, 211, 1915-1924.	1.9	36
21	Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany. <i>BMC Infectious Diseases</i> , 2015, 15, 137.	1.3	15
22	Transmission and Effect of Multiple Clusters of Seasonal Influenza in a Swiss Geriatric Hospital. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 739-744.	1.3	40
23	Vaccine-Preventable Travel Health Risks: What Is the Evidence? What Are the Gaps?. <i>Journal of Travel Medicine</i> , 2015, 22, 1-12.	1.4	67
25	Influenza vaccine effectiveness against laboratory confirmed influenza in Greece during the 2013-2014 season: A test-negative study. <i>Vaccine</i> , 2015, 33, 367-373.	1.7	13
26	Reply: Cochrane rearranged. <i>Vaccine</i> , 2015, 33, 12.	1.7	0
27	Influenza vaccines to control influenza-associated bacterial infection: where do we stand?. <i>Expert Review of Vaccines</i> , 2015, 14, 55-67.	2.0	20
28	T-Cell Immunity to Influenza in Older Adults: A Pathophysiological Framework for Development of More Effective Vaccines. <i>Frontiers in Immunology</i> , 2016, 7, 41.	2.2	124
29	Immunosenescence-Related Transcriptomic and Immunologic Changes in Older Individuals Following Influenza Vaccination. <i>Frontiers in Immunology</i> , 2016, 7, 450.	2.2	40
30	Influenza: from zoonosis to pandemic. <i>ERJ Open Research</i> , 2016, 2, 00013-2016.	1.1	25
31	The role of vaccination in successful independent ageing. <i>European Geriatric Medicine</i> , 2016, 7, 171-175.	1.2	9
32	The confounded effects of age and exposure history in response to influenza vaccination. <i>Vaccine</i> , 2016, 34, 540-546.	1.7	109
33	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1-18.	1.4	49
34	Ageing of the immune system: Focus on inflammation and vaccination. <i>European Journal of Immunology</i> , 2016, 46, 2286-2301.	1.6	329
35	Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics - a systematic literature review. <i>Influenza and Other Respiratory Viruses</i> , 2016, 10, 254-267.	1.5	66
36	One Against All: A Broadly Influenza Neutralizing Man-made Monoclonal Antibody Passes Phase I. <i>EBioMedicine</i> , 2016, 5, 16-17.	2.7	1
37	Influenza in the Emergency Department: Vaccination, Diagnosis, and Treatment: Clinical Practice Paper Approved by American Academy of Emergency Medicine Clinical Guidelines Committee. <i>Journal of Emergency Medicine</i> , 2016, 50, 536-542.	0.3	36
38	A cluster randomized controlled trial comparing relative effectiveness of two licensed influenza vaccines in US nursing homes: Design and rationale. <i>Clinical Trials</i> , 2016, 13, 264-274.	0.7	20

#	ARTICLE	IF	CITATIONS
39	Identification and characterization of influenza variants resistant to a viral endonuclease inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3669-3674.	3.3	51
40	Establishment of a cohort for deep phenotyping of the immune response to influenza vaccination among elderly individuals recruited from the general population. Human Vaccines and Immunotherapeutics, 2017, 13, 1630-1639.	1.4	7
41	Reply to: Estimating the Full Value of High-Dose Influenza Vaccine. Journal of the American Geriatrics Society, 2017, 65, 2111-2112.	1.3	1
42	Vaccines in the Prevention of Viral Pneumonia. Clinics in Chest Medicine, 2017, 38, 155-169.	0.8	8
43	Estimating influenza vaccine effectiveness: Evolution of methods to better understand effects of confounding in older adults. Vaccine, 2017, 35, 6269-6274.	1.7	22
44	Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination in a Cohort of Older Adults, Despite Effectively Reducing Laboratory-Confirmed Influenza Virus Infections. Journal of Infectious Diseases, 2017, 216, 415-424.	1.9	53
45	Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respiratory Medicine, 2017, 5, 738-746.	5.2	124
46	Benefits of flu vaccination for persons with diabetes mellitus: A review. Vaccine, 2017, 35, 5095-5101.	1.7	84
47	Cohort profile: the China Ageing REspiratory infections Study (CARES), a prospective cohort study in older adults in Eastern China. BMJ Open, 2017, 7, e017503.	0.8	7
48	Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials. Vaccine, 2017, 35, 4167-4176.	1.7	30
49	The life cycle of a T cell after vaccination – where does immune ageing strike?. Clinical and Experimental Immunology, 2016, 187, 71-81.	1.1	39
50	Test-Negative Design: The Importance of Laboratory-Confirmed Illness in Estimating the Effectiveness of Influenza Vaccine in Older Adults. Journal of Infectious Diseases, 2017, 216, 399-401.	1.9	3
51	Psychological determinants of influenza vaccination. BMC Geriatrics, 2017, 17, 194.	1.1	20
52	Moderate influenza vaccine effectiveness against influenza A(H1N1)pdm09 virus and low effectiveness against A(H3N2) virus among older adults during 2013–2014 influenza season in Beijing, China. Human Vaccines and Immunotherapeutics, 2018, 14, 1323-1330.	1.4	13
53	Factors influencing seasonal influenza vaccination behaviour among elderly people: a systematic review. Public Health, 2018, 156, 67-78.	1.4	96
54	Influenza vaccination in the elderly: Is a trial on mortality ethically acceptable?. Vaccine, 2018, 36, 2991-2997.	1.7	9
55	Vaccines for the elderly: current use and future challenges. Immunity and Ageing, 2018, 15, 3.	1.8	127
56	IL-1 β as mucosal vaccine adjuvant: the specific induction of tissue-resident memory T cells improves the heterosubtypic immunity against influenza A viruses. Mucosal Immunology, 2018, 11, 1265-1278.	2.7	67

#	ARTICLE	IF	CITATIONS
57	Factors affecting immune responses to the influenza vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 637-646.	1.4	65
58	Influenza vaccination in the elderly. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 540-549.	1.4	110
59	Influenza vaccination rates before and after admission to nursing homes in Germany. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 609-616.	1.4	6
60	Influenza Vaccination Beliefs and Practices in Elderly Primary Care Patients. <i>Journal of Community Health</i> , 2018, 43, 201-206.	1.9	9
61	Healthy elderly Singaporeans show no age-related humoral hypo-responsiveness nor diminished plasmablast generation in response to influenza vaccine. <i>Immunity and Ageing</i> , 2018, 15, 28.	1.8	10
62	La vaccination, ce n'est pas que pour les enfants, et c'est indispensable chez les patients diabétiques !. <i>Medecine Des Maladies Metaboliques</i> , 2018, 12, 441-446.	0.1	1
63	Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. <i>Science</i> , 2018, 362, 598-602.	6.0	170
64	The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine. <i>Frontiers in Immunology</i> , 2018, 9, 1479.	2.2	29
65	Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children 6 Months and Older Adults. <i>Vaccines</i> , 2018, 6, 14.	2.1	18
66	Healthy elderly and influenza vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2987-2989.	1.4	1
67	Sex and the Aging Immune System. , 2018, , 803-830.		1
68	Trajectories of seasonal influenza vaccine uptake among French people with diabetes: a nationwide retrospective cohort study, 2006-2015. <i>BMC Public Health</i> , 2019, 19, 918.	1.2	7
69	EXAMINING THE KNOWLEDGE, ATTITUDES AND EXPERIENCES OF CANADIAN SENIORS TOWARDS INFLUENZA (THE Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.1	17
70	Public Health-Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union. <i>Emerging Infectious Diseases</i> , 2019, 25, .	2.0	11
71	Influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. No impact on long-term mortality. <i>PLoS ONE</i> , 2019, 14, e0216983.	1.1	4
72	Comparison of influenza disease burden in older populations of Hong Kong and Brisbane: the impact of influenza and pneumococcal vaccination. <i>BMC Infectious Diseases</i> , 2019, 19, 162.	1.3	10
73	Adjuvanted influenza vaccine for the Italian elderly in the 2018/19 season: an updated health technology assessment. <i>European Journal of Public Health</i> , 2019, 29, 900-905.	0.1	10
74	Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1035-1047.	1.4	6

#	ARTICLE	IF	CITATIONS
75	Severe acute respiratory infections (SARI) from influenza in adult patients in Chile: the experience of a sentinel hospital. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2019, 43, 1-11.	0.6	9
77	Canadian older adults's perceptions of effectiveness and value of regular and high-dose influenza vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 487-495.	1.4	10
78	Influenza and Influenza Vaccination in Japanese Elderly. <i>Current Topics in Environmental Health and Preventive Medicine</i> , 2019, , 171-183.	0.1	0
79	Mass media coverage and influenza vaccine uptake. <i>Vaccine</i> , 2020, 38, 271-277.	1.7	34
80	Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China. <i>Vaccine</i> , 2020, 38, 1057-1064.	1.7	21
81	Frailty Is Associated With Increased Hemagglutination-Inhibition Titers in a 4-Year Randomized Trial Comparing Standard- and High-Dose Influenza Vaccination. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa148.	0.4	23
82	Seasonal influenza vaccination among older adults in Jordan: prevalence, knowledge, and attitudes. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2252-2256.	1.4	13
83	Inflamm-aging: the role of inflammation in age-dependent cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 2974-2982.	1.0	185
85	Non-ventilator health care-associated pneumonia (NV-HAP): Long-term care. <i>American Journal of Infection Control</i> , 2020, 48, A14-A16.	1.1	5
86	Innate signalling molecules as genetic adjuvants do not alter the efficacy of a DNA-based influenza A vaccine. <i>PLoS ONE</i> , 2020, 15, e0231138.	1.1	7
87	Vaccination in old age: Challenges and promises. , 2021, , 129-153.		1
88	T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine. <i>Viruses</i> , 2021, 13, 199.	1.5	21
89	Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons. <i>Clinical Infectious Diseases</i> , 2021, 73, 816-823.	2.9	30
90	Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review. <i>Vaccine</i> , 2021, 39, A42-A50.	1.7	11
91	Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United States. <i>Vaccine</i> , 2021, 39, A56-A69.	1.7	6
92	Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?. <i>Frontiers in Immunology</i> , 2021, 12, 673699.	2.2	16
93	Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - A phase III, active-controlled, randomized clinical study. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	9
94	The effect of influenza and pneumococcal vaccination in the elderly on health service utilisation and costs: a claims data-based cohort study. <i>European Journal of Health Economics</i> , 2022, 23, 67-80.	1.4	6

#	ARTICLE	IF	CITATIONS
95	Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1027-1037.	4.6	31
96	Influenza Viruses: Innate Immunity and mRNA Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 710647.	2.2	22
97	Risk Factors Associated with 30-Day Mortality in Older Patients with Influenza. <i>Journal of Clinical Medicine</i> , 2021, 10, 3521.	1.0	1
98	Prevalence of antibodies against seasonal influenza A and B viruses among older adults in rural Thailand: A cross-sectional study. <i>PLoS ONE</i> , 2021, 16, e0256475.	1.1	1
99	Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications. <i>Vaccines</i> , 2021, 9, 862.	2.1	15
100	Influenza Vaccines: Successes and Continuing Challenges. <i>Journal of Infectious Diseases</i> , 2021, 224, S405-S419.	1.9	24
101	Impact of video-led educational intervention on the uptake of influenza vaccine among adults aged 60 years and above in China: a study protocol for a randomized controlled trial. <i>BMC Public Health</i> , 2021, 21, 222.	1.2	4
103	A phase IIb study to determine the safety and efficacy of candidate Influenza Vaccine MVA-NP+M1 in combination with licensed Inactivated influenza vaccine in adults aged 65 years and above (INVICTUS): a study protocol. <i>F1000Research</i> , 2019, 8, 719.	0.8	14
104	Advances in influenza vaccination. <i>F1000prime Reports</i> , 2014, 6, 47.	5.9	18
105	Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages. <i>PLoS ONE</i> , 2015, 10, e0126650.	1.1	37
106	Net Costs Due to Seasonal Influenza Vaccination – United States, 2005–2009. <i>PLoS ONE</i> , 2015, 10, e0132922.	1.1	14
107	Cost-Effectiveness of Increasing Influenza Vaccination Coverage in Adults with Type 2 Diabetes in Turkey. <i>PLoS ONE</i> , 2016, 11, e0157657.	1.1	13
108	Prevention and Control of Seasonal Influenza with Vaccines. <i>MMWR Recommendations and Reports</i> , 2016, 65, 1-54.	26.7	357
109	Vaccine efficacy and T helper cell differentiation change with aging. <i>Oncotarget</i> , 2016, 7, 33581-33594.	0.8	31
110	Triggering of Toll-like Receptors in Old Individuals. Relevance for Vaccination. <i>Current Pharmaceutical Design</i> , 2019, 25, 4163-4167.	0.9	8
111	Real-time real-world analysis of seasonal influenza vaccine effectiveness: method development and assessment of a population-based cohort in Stockholm County, Sweden, seasons 2011/12 to 2014/15. <i>Eurosurveillance</i> , 2016, 21, .	3.9	13
112	The effectiveness of influenza vaccination in preventing hospitalisations of elderly individuals in two influenza seasons: a multicentre case-control study, Spain, 2013/14 and 2014/15. <i>Eurosurveillance</i> , 2017, 22, .	3.9	10
113	Trends in seasonal influenza vaccine coverage of target groups in France, 2006/07 to 2015/16: Impact of recommendations and 2009 influenza A(H1N1) pandemic. <i>Eurosurveillance</i> , 2018, 23, .	3.9	22

#	ARTICLE	IF	CITATIONS
114	Influenza – the need to stay ahead of the virus. Eurosurveillance, 2015, 20, 21030.	3.9	4
115	Influenza Vaccination and the End of Simplicity. Deutsches Ärzteblatt International, 2013, 110, 791-2.	0.6	0
116	Vaccination in Older Adults. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 563-576.	0.2	0
117	Effects of Ageing on the Vaccination Response. , 2017, , 69-86.		0
118	Preclinical Animal Models for Developing Vaccines Against Influenza Infection for the Young and the Elderly. , 2018, , 1-24.		0
119	Preclinical Animal Models for Developing Vaccines Against Influenza Infection for the Young and the Elderly. , 2019, , 39-62.		0
120	Adjuvanticity of Processed <i>Aloe vera</i> gel for Influenza Vaccination in Mice. Immune Network, 2020, 20, e31.	1.6	4
121	Interpandemic (seasonal) influenza. , 0, , 35-64.		0
122	Analyses of Merging Clinical and Viral Genetic Data for Influenza Surveillance. AMIA ... Annual Symposium proceedings, 2015, 2015, 1995-2004.	0.2	0
123	Potential impact of combined influenza and pneumococcal vaccines on the severity of respiratory illness in COVID-19 infection among type 2 diabetic patients. Clinical and Experimental Medicine, 2022, , 1.	1.9	2
124	Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis. Vaccine, 2022, 40, 994-1000.	1.7	5
125	The effect of standard-dose wintertime vitamin D supplementation on influenza infection in immunized nursing home elderly residents. Croatian Medical Journal, 2021, 62, 495-503.	0.2	1
126	Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults. Value in Health, 2022, 25, 1439-1458.	0.1	7
127	Age-dependent and sex-dependent differences in mortality from influenza-associated cardiovascular diseases among older adults in Shanghai, China: a population-based study. BMJ Open, 2022, 12, e061068.	0.8	1
128	Knowledge and perception regarding effectiveness in influenza vaccines among General Practitioners in Germany: A national survey. Vaccine: X, 2022, 12, 100236.	0.9	2
129	The effectiveness of influenza vaccine among elderly Chinese: A regression discontinuity design based on Yinzhou regional health information platform. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	2